Knee replacement.
Carr AJ, Robertsson O, Graves S, Price AJ, Arden NK, Judge A, Beard DJ.
Lancet. 2012 Apr 7;379(9823):1331-40. doi: 10.1016/S0140-6736(11)60752-6. Epub 2012 Mar 6.
Current insights of applying MRI in Graves' ophthalmopathy.
Song C, Luo Y, Yu G, Chen H, Shen J.
Front Endocrinol (Lausanne). 2022 Sep 29;13:991588. doi: 10.3389/fendo.2022.991588. eCollection 2022.
Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.
Salvi M, Vannucchi G, Currò N, Campi I, Covelli D, Dazzi D, Simonetta S, Guastella C, Pignataro L, Avignone S, Beck-Peccoz P.
J Clin Endocrinol Metab. 2015 Feb;100(2):422-31. doi: 10.1210/jc.2014-3014. Epub 2014 Dec 15.
Graves' ophthalmopathy: the clinical and psychosocial outcomes of different medical interventions - a systematic review.
Bello OM, Druce M, Ansari E.
BMJ Open Ophthalmol. 2024 Jun 17;9(1):e001515. doi: 10.1136/bmjophth-2023-001515.
Efficacy of selenium supplementation for patients with Graves' hyperthyroidism during methimazole treatment: protocol for a systematic review and meta-analysis.
Yuan S, Wen Q, Li M.
BMJ Open. 2024 Sep 24;14(9):e081302. doi: 10.1136/bmjopen-2023-081302.
Coloring between the Treatment Guidelines for Graves' Orbitopathy.
Mombaerts I.
Ophthalmology. 2020 Apr;127(4S):S158-S159. doi: 10.1016/j.ophtha.2019.09.045.
Clinical efficacy of Chinese herbal medicine formula for Graves' hyperthyroidism: A multicentre, randomized, double-blind, placebo-controlled clinical trial.
Gan D, Gao TS, Ma L, Lu H, Dai H, Liu QY, Lai YW, Liu XH, Peng ZD, Chen RY, Qiu ZY, Tong Y, Yan RX, Liu JH, Shen Q, Wang C, Yu SS, Chen SW, Liu XW, Chen XY, Zhang FN, Wang ZM, Wang YN, Yang X.
J Ethnopharmacol. 2025 Feb 10;338(Pt 3):119106. doi: 10.1016/j.jep.2024.119106. Epub 2024 Nov 15.
Surgical treatment of Graves' ophthalmopathy.
Eckstein A, Schittkowski M, Esser J.
Best Pract Res Clin Endocrinol Metab. 2012 Jun;26(3):339-58. doi: 10.1016/j.beem.2011.11.002.
Future Research in Graves' Orbitopathy: From Priority Setting to Trial Design Through Patient and Public Involvement.
Perros P, Dayan CM, Dickinson AJ, Ezra DG, Hickey JL, Hintschisch C, Kahaly G, Lazarus JH, Ludgate M, Bartès B, MacEwen CJ, Mitchell AL, Morris D, O'Connor N, Pearce SH, Rose GE, Salvi M, Wiersinga WM, Williamson A; Thyroid Eye Disease Amsterdam Declaration Implementation Group UK; European Group on Graves’ Orbitopathy.
Thyroid. 2015 Nov;25(11):1181-4. doi: 10.1089/thy.2015.0222. Epub 2015 Oct 14.
Is There a Correlation of TSI Levels and Incidental Papillary Thyroid Carcinoma in Graves Disease? A Review of the Latest Evidence.
Damaskos C, Garmpis N, Dimitroulis D, Kyriakos G, Diamantis E.
Acta Medica (Hradec Kralove). 2021;64(4):200-203. doi: 10.14712/18059694.2022.2.
